Ayala Pharmaceuticals (ADXS) Competitors $0.03 0.00 (-2.01%) As of 05/30/2025 09:35 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ADXS vs. BFRI, INDP, NLSP, SNGX, MTVA, ENSC, APLM, GTBP, FRTX, and ADILShould you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Biofrontera (BFRI), Indaptus Therapeutics (INDP), NLS Pharmaceutics (NLSP), Soligenix (SNGX), MetaVia (MTVA), Ensysce Biosciences (ENSC), Apollomics (APLM), GT Biopharma (GTBP), Fresh Tracks Therapeutics (FRTX), and Adial Pharmaceuticals (ADIL). These companies are all part of the "pharmaceutical products" industry. Ayala Pharmaceuticals vs. Biofrontera Indaptus Therapeutics NLS Pharmaceutics Soligenix MetaVia Ensysce Biosciences Apollomics GT Biopharma Fresh Tracks Therapeutics Adial Pharmaceuticals Biofrontera (NASDAQ:BFRI) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations. Which has more volatility & risk, BFRI or ADXS? Biofrontera has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, Ayala Pharmaceuticals has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Do institutionals & insiders have more ownership in BFRI or ADXS? 10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 1.2% of Biofrontera shares are owned by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate BFRI or ADXS? Biofrontera currently has a consensus price target of $2.75, suggesting a potential upside of 382.46%. Given Biofrontera's stronger consensus rating and higher probable upside, equities analysts plainly believe Biofrontera is more favorable than Ayala Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer BFRI or ADXS? In the previous week, Biofrontera had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Biofrontera and 0 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.00 beat Biofrontera's score of -0.03 indicating that Ayala Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Biofrontera Neutral Ayala Pharmaceuticals Neutral Does the MarketBeat Community favor BFRI or ADXS? Biofrontera received 9 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 69.23% of users gave Biofrontera an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBiofronteraOutperform Votes969.23% Underperform Votes430.77% Ayala PharmaceuticalsOutperform VotesNo VotesUnderperform Votes87100.00% Which has stronger earnings and valuation, BFRI or ADXS? Biofrontera has higher revenue and earnings than Ayala Pharmaceuticals. Biofrontera is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiofrontera$38.00M0.14-$20.13M-$2.26-0.25Ayala Pharmaceuticals$3.24M0.45-$48.07M-$7.980.00 Is BFRI or ADXS more profitable? Ayala Pharmaceuticals has a net margin of 0.00% compared to Biofrontera's net margin of -36.31%. Ayala Pharmaceuticals' return on equity of 0.00% beat Biofrontera's return on equity.Company Net Margins Return on Equity Return on Assets Biofrontera-36.31% -565.73% -96.64% Ayala Pharmaceuticals N/A N/A N/A SummaryBiofrontera beats Ayala Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXS vs. The Competition Export to ExcelMetricAyala PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.46M$6.59B$5.41B$8.39BDividend YieldN/A2.64%5.28%4.17%P/E Ratio0.008.6926.8519.76Price / Sales0.45237.36405.12134.19Price / CashN/A65.8538.2534.64Price / Book-0.026.336.784.51Net Income-$48.07M$143.71M$3.23B$247.95M7 Day PerformanceN/A1.14%1.29%1.01%1 Month PerformanceN/A-0.08%6.84%8.28%1 Year PerformanceN/A-2.46%25.24%8.91% Ayala Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXSAyala PharmaceuticalsN/A$0.03-2.0%N/A-86.3%$1.46M$3.24M0.0020Gap DownBFRIBiofrontera2.1986 of 5 stars$0.67+3.1%$2.75+310.5%-43.6%$6.33M$37.32M-0.3070Short Interest ↑Gap UpINDPIndaptus Therapeutics3.6044 of 5 stars$0.39-13.1%$8.50+2,079.5%-86.4%$6.25MN/A-0.236News CoveragePositive NewsShort Interest ↓Gap DownNLSPNLS PharmaceuticsN/A$1.71+5.8%N/A+1,301.9%$6.15MN/A0.006Positive NewsShort Interest ↓SNGXSoligenix1.0683 of 5 stars$1.88+1.1%N/A-66.2%$6.14M$-117,029.00-0.2520Gap UpMTVAMetaVia2.3545 of 5 stars$0.70+2.1%$7.50+973.0%N/A$6.05MN/A0.008Positive NewsGap DownENSCEnsysce Biosciences0.1136 of 5 stars$2.55+9.0%N/A-75.0%$6.05M$2.23M-0.0910Analyst UpgradeShort Interest ↑Gap UpAPLMApollomics0.373 of 5 stars$5.40+10.4%N/A-79.4%$5.96M$1.22M0.0045Short Interest ↑GTBPGT Biopharma3.574 of 5 stars$2.24+0.4%$11.00+391.1%-33.4%$5.68MN/A-0.398Gap UpFRTXFresh Tracks TherapeuticsN/A$0.94-0.5%N/A+1.6%$5.59M$10.06M-0.6620ADILAdial Pharmaceuticals2.7918 of 5 stars$0.70+6.4%$8.00+1,042.9%-54.5%$5.53MN/A-0.4820Short Interest ↑ Related Companies and Tools Related Companies Biofrontera Alternatives Indaptus Therapeutics Alternatives NLS Pharmaceutics Alternatives Soligenix Alternatives MetaVia Alternatives Ensysce Biosciences Alternatives Apollomics Alternatives GT Biopharma Alternatives Fresh Tracks Therapeutics Alternatives Adial Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXS) was last updated on 5/31/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADXS Stock Free ADXS Stock Alerts